FDA grants priority review for NUPLAZID supplemental application
The FDA has granted priority review status for the supplemental application of NUPLAZID (pimavanserin tartrate) submitted by ACADIA Pharmaceuticals.
Company
Pharmaceutical intelligence for ACADIA Pharmaceuticals with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
The FDA has granted priority review status for the supplemental application of NUPLAZID (pimavanserin tartrate) submitted by ACADIA Pharmaceuticals.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.